Drugs / KB001-A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01695343 | Dec 2012 → Nov 2014 | cystic fibrosis | Humanigen, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KB001-A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01695343 ↗ |
| Route | Intravenous | “administered up to 5x intravenously (IV) at 10 mg/kg up to a maximum dose of 800 mg per dose.” NCT01695343 ↗ |